Search Results
CARE Update in Hodgkin's Lymphoma by Dr. John Kuruvilla (Princess Margaret Cancer Centre)
Deep dive in diffuse large B cell lymphoma: Webcast - Dr. Kuruvilla, Princess Margaret Cancer Centre
Hodgkin lymphoma highlights at ASH 2022 and future outlooks
Dr. Kuruvilla on the Safety of Pembrolizumab in Classical Hodgkin Lymphoma
T Cell Engager Antibodies – focus on Hematological Malignancies | Presented by Dr. John Kuruvilla
Panel Discussion | Dr. Marcus Butler, Dr. Naoto Hirano, Dr. John Kuruvilla and Dr. Guy Ungerechts
Understanding the balance between efficacy and toxicity
Dr. Kuruvilla on the Treatment Landscape in Relapsed/Refractory Hodgkin Lymphoma
Possibilities for the use of pembrolizumab in lymphoma treatment
Checkpoint inhibitors in Hodgkin lymphoma
Outcomes of patients with Hodgkin lymphoma undergoing alloHSCT after pembrolizumab therapy
QoL of patients with R/R Hodgkin lymphoma treated with pembrolizumab vs brentuximab vedotin
